Skip to main content
Top
Published in: Current Rheumatology Reports 3/2015

01-03-2015 | Crystal Arthritis (MH Pillinger and S Krasnokutsky, Section Editors)

Hyperuricemia, Gout, and Cardiovascular Disease: An Update

Author: Aryeh M. Abeles

Published in: Current Rheumatology Reports | Issue 3/2015

Login to get access

Abstract

Across the globe, both gout and hyperuricemia have become increasingly common over the last few decades. The burden of gouty disease is made heavier by its association with several comorbid conditions, including hypertension, cardiovascular disease, and chronic kidney disease. Accruing evidence from prospective studies suggests that gout is an independent risk factor for developing cardiovascular disease and for higher cardiovascular mortality. While asymptomatic hyperuricemia does not seem to be an independent risk factor for cardiovascular disease, increasing data implicates hyperuricemia as a risk factor for developing incidental hypertension. Important questions that remain unanswered include whether addressing asymptomatic hyperuricemia forestalls the onset of hypertension, and whether treating gout with urate-lowering agents improves cardiovascular outcomes. This article reviews the most recent data regarding the relationship between hyperuricemia, gout, hypertension, and cardiovascular disease, as well as emerging evidence as to whether treatment of hyperuricemia and gout improves cardiovascular outcomes.
Literature
1.
go back to reference Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.CrossRefPubMed Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.CrossRefPubMed
2.
go back to reference Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993–1996 to 2005–2008. Asia Pac J Clin Nutr. 2011;20(2):301–8.PubMed Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993–1996 to 2005–2008. Asia Pac J Clin Nutr. 2011;20(2):301–8.PubMed
3.
go back to reference Keenan RT, O’Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155–63.CrossRefPubMed Keenan RT, O’Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155–63.CrossRefPubMed
4.
go back to reference Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case–control study. Ann Rheum Dis. 2014. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case–control study. Ann Rheum Dis. 2014.
5.
go back to reference Mahomed FA. On chronic Bright’s disease, and its essential symptoms. Lancet. 1879;1:399–401.CrossRef Mahomed FA. On chronic Bright’s disease, and its essential symptoms. Lancet. 1879;1:399–401.CrossRef
7.
go back to reference Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275(9):457–64.CrossRefPubMed Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275(9):457–64.CrossRefPubMed
8.
go back to reference Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.CrossRefPubMed Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.CrossRefPubMed
9.
go back to reference Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295(4):F1134–41.CrossRefPubMedCentralPubMed Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295(4):F1134–41.CrossRefPubMedCentralPubMed
10.
go back to reference Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–75.CrossRefPubMed Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–75.CrossRefPubMed
11.
go back to reference Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991–7.CrossRefPubMed Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991–7.CrossRefPubMed
12.
go back to reference van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245.CrossRefPubMedCentralPubMed van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245.CrossRefPubMedCentralPubMed
13.
go back to reference Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355–60.CrossRefPubMed Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355–60.CrossRefPubMed
15.
go back to reference Selby JV, Friedman GD, Quesenberry Jr CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990;131(6):1017–27.PubMed Selby JV, Friedman GD, Quesenberry Jr CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990;131(6):1017–27.PubMed
16.
go back to reference Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–30.CrossRefPubMed Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–30.CrossRefPubMed
17.
go back to reference Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.CrossRefPubMed Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.CrossRefPubMed
18.
go back to reference Yang T, Chu CH, Bai CH, You SL, Chou YC, Hwang LC, et al. Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: a Chinese cohort study. Metabolism. 2012;61(12):1747–55.CrossRefPubMed Yang T, Chu CH, Bai CH, You SL, Chou YC, Hwang LC, et al. Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: a Chinese cohort study. Metabolism. 2012;61(12):1747–55.CrossRefPubMed
19.
go back to reference Gaffo AL, Jacobs DR, Sijtsma F, Lewis CE, Mikuls TR, Saag KG. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis. 2013;72:1321–7.CrossRefPubMed Gaffo AL, Jacobs DR, Sijtsma F, Lewis CE, Mikuls TR, Saag KG. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis. 2013;72:1321–7.CrossRefPubMed
20.
go back to reference Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18:287–92.CrossRefPubMed Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18:287–92.CrossRefPubMed
21.•
go back to reference van Durme C, van Echteld IA, Falzon L, Aletaha D, van der Heijde DM, Landewé RB. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature. J Rheumatol Suppl. 2014;92:9–14. Exhaustive but concise review of all literature to date regarding hyperuricemia, gout, and cardiovascular disease, focusing on less-biased studies.CrossRefPubMed van Durme C, van Echteld IA, Falzon L, Aletaha D, van der Heijde DM, Landewé RB. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature. J Rheumatol Suppl. 2014;92:9–14. Exhaustive but concise review of all literature to date regarding hyperuricemia, gout, and cardiovascular disease, focusing on less-biased studies.CrossRefPubMed
22.•
go back to reference Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259. This meta-analysis exhaustively reviewed the literature on hyperuricemia and hypertension and concluded that hyperuricemia increases the risk of incidental hypertension in a dose-dependent manner.CrossRefPubMedCentralPubMed Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259. This meta-analysis exhaustively reviewed the literature on hyperuricemia and hypertension and concluded that hyperuricemia increases the risk of incidental hypertension in a dose-dependent manner.CrossRefPubMedCentralPubMed
23.
go back to reference Gois PH, Luchi WM, Seguro AC. Allopurinol on hypertension: insufficient evidence to recommend. J Clin Hypertens (Greenwich). 2013;15(9):700.CrossRef Gois PH, Luchi WM, Seguro AC. Allopurinol on hypertension: insufficient evidence to recommend. J Clin Hypertens (Greenwich). 2013;15(9):700.CrossRef
24.•
go back to reference Gois PH, Souza ER. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev. 2013;1:CD008652. A systematic review on anti-hypertensives for hyperuricemia that underscores the need for prospective clinical trials.PubMed Gois PH, Souza ER. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev. 2013;1:CD008652. A systematic review on anti-hypertensives for hyperuricemia that underscores the need for prospective clinical trials.PubMed
25.
go back to reference Song K, Wang Y, Wang G, Zhang Q, Jiao H, et al. Does decreasing serum uric acid level prevent hypertension?—a nested RCT in cohort study: rationale, methods, and baseline characteristics of study cohort. BMC Public Health. 2013;13:1069.CrossRefPubMedCentralPubMed Song K, Wang Y, Wang G, Zhang Q, Jiao H, et al. Does decreasing serum uric acid level prevent hypertension?—a nested RCT in cohort study: rationale, methods, and baseline characteristics of study cohort. BMC Public Health. 2013;13:1069.CrossRefPubMedCentralPubMed
26.
go back to reference Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62(2):170–80. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62(2):170–80.
27.
go back to reference Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007;58:450–7.CrossRefPubMed Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007;58:450–7.CrossRefPubMed
28.
go back to reference Vinik O, Wechalekar MD, Falzon L, Buchbinder R, van der Heijde DM, Bombardier C. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. J Rheumatol Suppl. 2014;92:70–4.CrossRefPubMed Vinik O, Wechalekar MD, Falzon L, Buchbinder R, van der Heijde DM, Bombardier C. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. J Rheumatol Suppl. 2014;92:70–4.CrossRefPubMed
29.
go back to reference Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688–96.CrossRefPubMed Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688–96.CrossRefPubMed
30.
go back to reference De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69(6):1162–4.CrossRefPubMedCentralPubMed De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69(6):1162–4.CrossRefPubMedCentralPubMed
31.
go back to reference Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52(1):111–7.CrossRef Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52(1):111–7.CrossRef
32.•
go back to reference Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-205252. Large and well-performed retrospective cohort study that implicates gout in cardiovascular disease. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink. Ann Rheum Dis. 2014. doi:10.​1136/​annrheumdis-2014-205252. Large and well-performed retrospective cohort study that implicates gout in cardiovascular disease.
33.
go back to reference Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251–9.CrossRef Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251–9.CrossRef
34.
go back to reference Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. 2012;71:924–8.CrossRefPubMedCentralPubMed Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. 2012;71:924–8.CrossRefPubMedCentralPubMed
35.
go back to reference Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900.CrossRefPubMed Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900.CrossRefPubMed
36.
go back to reference Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104–10.CrossRefPubMed Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104–10.CrossRefPubMed
37.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.CrossRefPubMed
38.
go back to reference Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.CrossRefPubMed Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.CrossRefPubMed
39.•
go back to reference Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, et al. the PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2012-202972. Recent study that concludes that suggests allopurinol use decreases the risk of myocardial infarction in a gout cohort.PubMed Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, et al. the PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2014. doi:10.​1136/​annrheumdis-2012-202972. Recent study that concludes that suggests allopurinol use decreases the risk of myocardial infarction in a gout cohort.PubMed
40.
go back to reference Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–64.CrossRefPubMedCentralPubMed Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–64.CrossRefPubMedCentralPubMed
41.•
go back to reference Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS One. 2014;9(6):e99102. Despite the title of the paper, this study demonstrates that allopurinol therapy decreases the rate of cardiovascular disease, in doses over 100 mg daily.CrossRefPubMedCentralPubMed Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS One. 2014;9(6):e99102. Despite the title of the paper, this study demonstrates that allopurinol therapy decreases the rate of cardiovascular disease, in doses over 100 mg daily.CrossRefPubMedCentralPubMed
42.
go back to reference Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87–114.CrossRefPubMedCentralPubMed Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87–114.CrossRefPubMedCentralPubMed
Metadata
Title
Hyperuricemia, Gout, and Cardiovascular Disease: An Update
Author
Aryeh M. Abeles
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 3/2015
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0495-2

Other articles of this Issue 3/2015

Current Rheumatology Reports 3/2015 Go to the issue

Crystal Arthritis (MH Pillinger and S Krasnokutsky, Section Editors)

The Gouty Tophus: a Review

Pediatric Rheumatology (S Ozen, Section Editor)

Reviewing the Recommendations for Lupus in Children

Vasculitis (L Espinoza, Section Editor)

New Insights on Biomarkers in Systemic Vasculitis

Pediatric Rheumatology (S Ozen, Section Editor)

Update on Juvenile Systemic Sclerosis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.